Drug Profile


Alternative Names: AR-119; BAY-86-9766; RDEA-119; VRX-119

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Ardea Biosciences; Bayer HealthCare
  • Class Aniline compounds; Anti-inflammatories; Antineoplastics; Small molecules; Sulfonamides
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma
  • Phase I/II Pancreatic cancer; Solid tumours
  • Discontinued Inflammation

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Hepatocellular carcinoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 07 Oct 2015 Bayer completes enrolment in its phase Ib/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (NCT02168777)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top